The Latest Cardiac and Vascular News
Company joins Downtown North Urban Insight District in unique mixed-use space to accommodate growing surgical robotics business ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global […]
ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic electrophysiology program with installation of Stereotaxis’ Robotic Magnetic Navigation technology. […]
ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona. HonorHealth is […]
ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to […]
ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China. The agreement brings together MicroPort EP’s commercial and product leadership in […]
ST. LOUIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2021. “Renewed global adoption of robotic systems continues to drive robust double digit revenue growth for Stereotaxis,” […]
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive […]
ST. LOUIS, May 10, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021. “The highlight of the first quarter is Stereotaxis’ return to robust double digit revenue growth with […]
ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said […]
ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020. “Stereotaxis is pleased to report revenue growth with the successful installation of the first Genesis RMN® and […]
